Among the initial crop of products there may not be a killer app yet, but these first offerings will enable Helix and partners to begin to understand their customer base.
A curation working group established a framework that considers the nature and strength of the available evidence when evaluating gene-disease associations.
Separate studies in NEJM from Regeneron Pharmaceuticals and Ionis Pharmaceuticals target the ANGPTL3 gene in an effort to develop heart disease treatments.
Respondents to a 2013 survey described changes in the way hereditary breast and ovarian cancer risk is assessed, interpreted, and conveyed to patients following the court decision.
The DiscovEHR study, conducted by the Regeneron Genetics Center and the Geisinger Health System, uncovered many associations between genetic variants and clinical phenotypes.
The Pharmacogenomics Clinical Annotation Tool interprets variants from sequencing or genotyping tests and generates a report to inform prescribing decisions.
